Flputnam Investment Management Co. Has $1.52 Million Stock Position in Becton, Dickinson and Company $BDX

Flputnam Investment Management Co. boosted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 293.8% in the second quarter, Holdings Channel reports. The firm owned 10,080 shares of the medical instruments supplier’s stock after purchasing an additional 7,520 shares during the quarter. Flputnam Investment Management Co.’s holdings in Becton, Dickinson and Company were worth $1,525,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Auto Owners Insurance Co increased its holdings in Becton, Dickinson and Company by 22,225.2% during the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after buying an additional 40,528,680 shares during the last quarter. BlackRock Inc. acquired a new stake in Becton, Dickinson and Company during the second quarter worth approximately $3,721,533,000. Wellington Management Group LLP lifted its holdings in Becton, Dickinson and Company by 9,056.3% during the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock worth $979,290,000 after purchasing an additional 5,174,944 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in shares of Becton, Dickinson and Company by 23,219.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock valued at $769,397,000 after acquiring an additional 4,137,888 shares during the period. Finally, Norges Bank bought a new stake in Becton, Dickinson and Company in the 4th quarter valued at about $734,321,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 0.1%

Shares of BDX stock opened at $189.71 on Monday. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The stock’s fifty day moving average price is $166.14 and its two-hundred day moving average price is $160.20. The company has a market cap of $52.27 billion, a PE ratio of 57.14, a P/E/G ratio of 13.36 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter in the prior year, the business earned $3.68 earnings per share. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 126.51%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the sale, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 9,105 shares of company stock valued at $1,590,208. Company insiders own 0.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on BDX shares. Bank of America reduced their price target on Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Jefferies Financial Group reissued a “buy” rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Evercore set a $180.00 price target on Becton, Dickinson and Company in a research note on Monday, July 6th. Finally, UBS Group began coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They set a “buy” rating and a $190.00 price objective on the stock. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and an average price target of $185.67.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.